ADIPOQ and hepatocellular carcinoma: Consonant with this hypothesis, the administration of adiponectin (5 μg/kg weekly) blocked tumor progression in a thioacetamide-induced rat HCC model, resulting in an 80% increased survival rate, 73% reduced average number of nodules and 46% decreased serum AFP [51].